TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01763827

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to Ezetimibe
Description: Administered orally once daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to Ezetimibe
Description: Administered orally once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Ezetimibe
Description: Administered orally once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Ezetimibe
Description: Administered orally once daily
Study: NCT01127048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suppositories containing Ivy leaves dry extract
Description: Suppositories containing Ivy leaves dry extract

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suppositories containing no Ivy leaves dry extract
Study: NCT01293747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol + Progesterone
Description: Estradiol 1 mg and progesterone 20 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol + Progesterone
Description: Estradiol 0.5 mg and progesterone 15 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.
Study: NCT01912794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory Intervention
Description: 1. full sensory information, whose participants will practice balancing tasks without constraint sensory body;~2. sensory constraint, whose participants will practice the same balance tasks with constraint body of visual and tactile information from the soles of the feet;~3. control, whose participants will exercise activities involving cognitive and upper limbs.
Study: NCT01420237

Intervention type: DEVICE
Group type: OTHER
Intervention: Restoration ADM X3 Device
Description: Restoration ADM X3 Device in total hip replacement.
Study: NCT03026127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Reappraisal Intervention for Suicide Prevention
Description: Cognitive Reappraisal Intervention for Suicide Prevention, or CRISP, is a psychosocial intervention aimed to reduce suicide risk in middle-aged and older adults who have been hospitalized for suicidal ideation or suicide attempt. CRISP offers a combination of emotion regulation techniques, including changing the subject's perspective or the way he/she thinks to improve emotion reactions. Additional strategies taught include the provision of environmental adaptation tools (notes, checklists, calendars, etc), phone calls, and a tablet application called WellPATH.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Description: ST focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors
Study: NCT04332367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab IV
Study: NCT04573946

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day.~Other Names: cholecalciferol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day.~Other Names: cholecalciferol
Study: NCT03994653

Intervention type: OTHER
Intervention: Risk Factor Questionnaire
Description: For cases, the study recruiter at the Trust will present this in the clinic. Controls will complete this online or at home when volunteering to participate. The participant questionnaire will be completed by the participant.

Intervention type: OTHER
Intervention: Risk Factor Questionnaire
Description: For cases, the study recruiter at the Trust will present this in the clinic. Controls will complete this online or at home when volunteering to participate. The participant questionnaire will be completed by the participant.

Intervention type: OTHER
Intervention: Clinical Questionnaire
Description: For cases, the study recruiter at the trust will complete this form together with the participant. Controls will not complete this form.
Study: NCT01731327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib modified-release (MR) formulation
Description: A single dose of 11 mg tofacitinib modified-release (MR) administered in a fasting state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib modified-release (MR) formulation
Description: A single dose of 22 mg tofacitinib modified-release (MR) administered in a fasting state.
Study: NCT02483988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NUsurface® Meniscus Implant
Description: The NUsurface® Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network that supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
Study: NCT01726465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone is a glucocorticoid, which is an adrenocortical steroid. The chemical name for methylprednisolone is pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6α,11β)-and the molecular weight is 374.48. It is an analog of naturally occurring glucocorticoid (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Methylprednisolone is used for their potent anti-inflammatory effects in disorders of many organ systems, it modify the body's immune responses to diverse stimuli. The usual dosage of medication varies in relation to pathology for which is prescribed: normally varies from about 40-60 mg per day up to very high doses of 30 mg/kg bolus as used in spinal cord injury.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Acetylcysteine is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. Chemically, it is N-acetyl-L-cysteine. The compound is a white crystalline powder which melts at 104°-110°C and has a very slight odor. Acetylcysteine may form cysteine, disulfides, and conjugates in vivo (N, N'-diacetylcysteine, N-acetylcysteine- cysteine, N-acetylcysteine-glutathione, N-acetylcysteine-protein, etc). No metabolites were identified. Acetylcysteine likely protects the liver by maintaining or restoring the glutathione levels, or by acting as an alternate substrate for conjugation with, and thus detoxification of, the reactive metabolite.
Study: NCT03697941

Intervention type: PROCEDURE
Intervention: Percutaneous arteriotomy closed using a plug-based arteriotomy closure device
Description: Percutaneous arteriotomy closed using a plug-based arteriotomy closure device (MANTA, Essential Medical Inc., Malvern, Pennsylvania).

Intervention type: PROCEDURE
Intervention: Surgical cut-down and arterial puncture under direct vision
Description: Surgical cut-down and arterial puncture under direct vision.
Study: NCT00758498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: armodafinil
Description: 50 mg/day orally, once daily in the morning for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: armodafinil
Description: 150 mg/day orally, once daily in the morning for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets, once daily in the morning for 3 days
Study: NCT01563198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comfort Talk®
Description: Personnel of MRI units will be trained in advanced rapport skills, patient-centered and hypnoidal language, correct use of suggestions and skills of tension diffusion. This will entail 16 hrs class room work, additional on-site post-training support, and access to a post-training support web module resulting in at least 20 hrs training.
Study: NCT01310127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac
Description: bromfenac 0.9% QD starting 3 days prior to cataract surgery, on the day of surgery and for up to 45 days after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac
Description: nepafenac ophthalmic suspension 0.1% TID dosed 3 days prior to cataract surgery, on the day of surgery, and for up to 45 days after surgery
Study: NCT00610272

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 4 Gy single fraction; mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), \>4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after \> 4 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 8 Gy single fraction, mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), \>4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after \> 4 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 8 Gy in a single fraction; retreatments \> 4 weeks, using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy) ; second reirradiation with 8 Gy using local RT fields optional (at discretion of PI);

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 12 Gy in 4 fractions of 3 Gy in 2 consecutive days interfraction interval of a minimum of 6 hrs; retreatments \> 4 weeks using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy); second reirradiation with 8 Gy using local RT fields optional (at discretion of PI) ;
Study: NCT02366299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Treatment of delirium by dexmedetomidine i.v. infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Treatment of delirium by Propofol i.v. infusion
Study: NCT03162042

Intervention type: PROCEDURE
Intervention: Tumor removal
Description: Surgery

Intervention type: PROCEDURE
Intervention: Tumor removal
Description: Surgery
Study: NCT04447469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mavrilimumab
Description: anti-granulocyte-macrophage colony-stimulating factor receptor alpha (GM-CSF-Rα) monoclonal antibody (human isoform immunoglobulin G \[IgG4\])

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mavrilimumab
Description: anti-granulocyte-macrophage colony-stimulating factor receptor alpha (GM-CSF-Rα) monoclonal antibody (human isoform immunoglobulin G \[IgG4\])

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mavrilimumab
Description: anti-granulocyte-macrophage colony-stimulating factor receptor alpha (GM-CSF-Rα) monoclonal antibody (human isoform immunoglobulin G \[IgG4\])

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mavrilimumab
Description: anti-granulocyte-macrophage colony-stimulating factor receptor alpha (GM-CSF-Rα) monoclonal antibody (human isoform immunoglobulin G \[IgG4\])
Study: NCT03017391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide
Description: metoclopramide 10 mg tablets 3x daily orally or suppositories 10 mg 3x daily rectally, use until toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide
Description: metoclopramide 10 mg tablets 3x daily orally or suppositories 10 mg 3x daily rectally, use until toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: granisetron
Description: granisetron patch 3.1mg/24 hours, use until toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: granisetron
Description: granisetron patch 3.1mg/24 hours, use until toxicity
Study: NCT04447469

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT03017391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone 8 mg, last step in both algorithms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone 8 mg, last step in both algorithms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron 2Mg Tablet
Description: granisetron 2 mg loading dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron 2Mg Tablet
Description: granisetron 2 mg loading dose
Study: NCT02052297

Intervention type: OTHER
Group type: OTHER
Intervention: GSK2634673F
Description: GSK2634673F is a synthetic peptide derived from the foot and mouth disease virus (FMDV2). GSK2634673F will be injected into a cubital or forearm vein intravenously and emission data acquired for up to 240 minutes. This radioactive ligand binds potently and specifically to the integrin alpha(V)beta6.

Intervention type: OTHER
Group type: OTHER
Intervention: GSK2634673F
Description: GSK2634673F is a synthetic peptide derived from the foot and mouth disease virus (FMDV2). GSK2634673F will be injected into a cubital or forearm vein intravenously and emission data acquired for up to 240 minutes. This radioactive ligand binds potently and specifically to the integrin alpha(V)beta6.

Intervention type: OTHER
Group type: OTHER
Intervention: GSK2634673F
Description: GSK2634673F is a synthetic peptide derived from the foot and mouth disease virus (FMDV2). GSK2634673F will be injected into a cubital or forearm vein intravenously and emission data acquired for up to 240 minutes. This radioactive ligand binds potently and specifically to the integrin alpha(V)beta6.
Study: NCT01420250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Administered weekly on the same day of radiation according to the following infusion levels:~Level 1 (Initial): 4 mg/m2; Level -1: 2 mg/m2; Level 2: 6 mg/m2; Level 3: 8 mg/m2; Level 4: 10 mg/2;

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: Starts 8 weeks after initiation of androgen deprivation therapy, given daily at 1.8 Gy for a total of 75.6 Gy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Androgen Therapy: Bicalutamide
Description: * Taken once daily by mouth starting between 2 weeks and 1 day before the first administration of Luteinizing Hormone-Releasing Hormone (LHRH)~* Will continue once daily until the final day of IMRT

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Description: * First administration will occur 1 day to 2 weeks after the start of Bicalutamide and 8 weeks prior to the start of IMRT (+/- 4 weeks)~* Will continue for 24 months after IMRT~* Total administered duration and agent used must be documented on the case report form
Study: NCT01738919

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment with splinting for 6 weeks.
Description: Aluminum Karstam splints are used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative treatment with extension block technique
Description: Surgery with extension block technique. 6 weeks.
Study: NCT00652145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesalamine
Description: Increase dose by 2.4gm per day over baseline dose
Study: NCT01639144

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP and PPP
Description: Autogenous PRP and PPP
Study: NCT02937740

Intervention type: DRUG
Group type: OTHER
Intervention: NATESTO Testosterone Nasal Gel
Description: Participants will be instructed to administer 5.5 mg of testosterone (1 actuation) per nostril of NATESTO Testosterone Nasal Gel once in the morning and once in the evening (at least 6 hours apart), preferably at the same time each day for a total daily dose of 22 mg/day of testosterone. Patients should be instructed to completely depress the pump 1 time in each nostril to receive the total dose.~For three times daily (after Visit 4 \[Day 90\] if symptoms not adequately managed by a BID dose), NATESTO will be administered intranasally once in the morning, once in the afternoon and once in the evening (approximately 6-8 hours apart), preferably at the same time each day for a total daily dose of 33 mg/day of testosterone.

Intervention type: DRUG
Group type: OTHER
Intervention: NATESTO Testosterone Nasal Gel
Description: Participants will be instructed to administer 5.5 mg of testosterone (1 actuation) per nostril of NATESTO Testosterone Nasal Gel once in the morning and once in the evening (at least 6 hours apart), preferably at the same time each day for a total daily dose of 22 mg/day of testosterone. Patients should be instructed to completely depress the pump 1 time in each nostril to receive the total dose.~For three times daily (after Visit 4 \[Day 90\] if symptoms not adequately managed by a BID dose), NATESTO will be administered intranasally once in the morning, once in the afternoon and once in the evening (approximately 6-8 hours apart), preferably at the same time each day for a total daily dose of 33 mg/day of testosterone.
Study: NCT04566718

Intervention type: DRUG
Intervention: Metformin
Description: metformin cessation

Intervention type: DRUG
Intervention: Metformin
Description: metformin cessation
Study: NCT02608996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nesiritide
Description: This intervention is designed to determine the optimal dose range of BNP for treatment of patients with uncontrolled hypertension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For comparison to elucidate the true effect of nesiritide
Study: NCT01516489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 1
Description: Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 1
Description: Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 1
Description: Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 2
Description: Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to. The exact dollar amounts for the Voucher-Based Incentive, Lottery-Based Incentive, and Raffle-Based Incentive arms will be based on the results of Stage 1.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 2
Description: Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to. The exact dollar amounts for the Voucher-Based Incentive, Lottery-Based Incentive, and Raffle-Based Incentive arms will be based on the results of Stage 1.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 2
Description: Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to. The exact dollar amounts for the Voucher-Based Incentive, Lottery-Based Incentive, and Raffle-Based Incentive arms will be based on the results of Stage 1.
Study: NCT04203212

Intervention type: DRUG
Intervention: Goserelin Acetate
Description: Goserelin the a GnRH analog that will be administered to achieve menstrual cessation for 6 months